Tango Therapeutics Inc
TNGX6.590USD
+0.060+0.92%
收盤 08/04, 16:00（美東）報價延遲15分鐘
712.43M總市值
虧損本益比TTM
關於 Tango Therapeutics Inc 公司
Tango Therapeutics, Inc. 是一家臨牀階段的生物技術公司，致力於發現新型藥物靶點並提供用於治療癌症的精準醫療。該公司利用合成致死的遺傳原理來發現和開發針對癌症關鍵靶點的療法。這包括將精準腫瘤學靶點的範圍擴展到新領域，例如腫瘤抑制基因缺失及其對癌細胞逃避免疫細胞殺傷能力的貢獻。其主要項目 TNG908 是一種甲硫腺苷 (MTA) 協同抑制劑，可抑制蛋白質精氨酸甲基轉移酶 5 (PRMT5)，旨在選擇性地作用於甲硫腺苷磷酸化酶 (MTAP) 缺失的癌細胞。其 TNG260 是同類首創的抑制元件 1 沉默轉錄 (CoREST) 的輔抑制劑。該公司的項目還包括 TNG348 和 TNG462。 TNG348 是泛素特異性蛋白酶 (USP1) 的變構抑制劑。
公司簡介
公司代碼TNGX
公司名稱Tango Therapeutics Inc
上市日期Sep 03, 2020
CEODr. Barbara Weber, M.D.
員工數量155
證券類型Ordinary Share
年結日Sep 03
公司地址201 Brookline Avenue
城市BOSTON
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編02215
電話18573204900
網址https://www.tangotx.com/
公司代碼TNGX
上市日期Sep 03, 2020
CEODr. Barbara Weber, M.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Ms. Lesley Ann Calhoun
Ms. Lesley Ann Calhoun
Independent Director
Independent Director
6.25K
--
Mr. Elizabeth Hickin
Mr. Elizabeth Hickin
Vice President, IR and Corporate Communications
Vice President, IR and Corporate Communications
--
--
Dr. Barbara Weber, M.D.
Dr. Barbara Weber, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. John Ketchum
Mr. John Ketchum
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Ms. Daniella Beckman, CPA
Ms. Daniella Beckman, CPA
Chief Financial Officer
Chief Financial Officer
98.90K
+6.68%
Dr. Adam S. Crystal, M.D., Ph.D.
Dr. Adam S. Crystal, M.D., Ph.D.
President - Research and Development
President - Research and Development
69.70K
+5.90%
Mr. Douglas Barry
Mr. Douglas Barry
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
Chief Legal Officer, Chief Compliance Officer, Corporate Secretary
23.55K
-64.32%
Dr. Malte Peters, M.D.
Dr. Malte Peters, M.D.
Independent Director
Independent Director
11.25K
+125.00%
Mr. Alexis Borisy
Mr. Alexis Borisy
Independent Chairman of the Board
Independent Chairman of the Board
11.25K
+125.00%
Dr. Mace Rothenberg, M.D.
Dr. Mace Rothenberg, M.D.
Independent Director
Independent Director
11.25K
+125.00%
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月2日 週六
更新時間: 8月2日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
持股股東
持股股東
佔比
Third Rock Ventures, LLC
15.55%
TCG Crossover Management, LLC
9.90%
EcoR1 Capital, LLC
9.81%
Boxer Capital Management, LLC
9.58%
Farallon Capital Management, L.L.C.
6.63%
Other
48.53%
股東類型
持股股東
佔比
Investment Advisor
34.87%
Hedge Fund
24.69%
Investment Advisor/Hedge Fund
19.20%
Venture Capital
16.29%
Corporation
11.03%
Individual Investor
1.57%
Research Firm
1.15%
Family Office
0.65%
Private Equity
0.51%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
311
118.45M
109.28%
-17.53M
2025Q1
320
116.84M
107.85%
-22.33M
2024Q4
310
116.06M
107.37%
-22.45M
2024Q3
292
115.54M
108.00%
-9.29M
2024Q2
286
112.62M
105.54%
-13.62M
2024Q1
280
112.63M
105.80%
-9.88M
2023Q4
261
107.66M
105.42%
-11.67M
2023Q3
235
102.78M
102.09%
+4.42M
2023Q2
224
81.67M
92.47%
-10.11M
2023Q1
216
83.27M
94.51%
-3.16M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Third Rock Ventures, LLC
16.86M
15.55%
-194.17K
-1.14%
Apr 01, 2025
TCG Crossover Management, LLC
10.74M
9.9%
--
--
Mar 31, 2025
EcoR1 Capital, LLC
10.63M
9.81%
--
--
Mar 31, 2025
Boxer Capital Management, LLC
10.38M
9.58%
--
--
Mar 31, 2025
Farallon Capital Management, L.L.C.
7.18M
6.63%
+2.57M
+55.76%
Jun 06, 2025
Nextech Invest, Ltd.
5.53M
5.11%
--
--
Mar 31, 2025
Gilead Sciences Inc
4.85M
4.48%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.88M
3.58%
-98.30K
-2.47%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.74M
3.45%
-110.35K
-2.87%
Mar 31, 2025
T. Rowe Price Investment Management, Inc.
3.31M
3.06%
-33.10K
-0.99%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Virtus LifeSci Biotech Clinical Trials ETF
0.91%
iShares Micro-Cap ETF
0.08%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
iShares Biotechnology ETF
0.03%
ProShares UltraPro Russell2000
0.02%
Global X Russell 2000 ETF
0.02%
iShares Russell 2000 Value ETF
0.02%
Proshares Ultra Russell 2000
0.02%
ProShares Hedge Replication ETF
0.02%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
佔比0.91%
iShares Micro-Cap ETF
佔比0.08%
ProShares Ultra Nasdaq Biotechnology
佔比0.06%
Invesco Nasdaq Biotechnology ETF
佔比0.06%
iShares Biotechnology ETF
佔比0.03%
ProShares UltraPro Russell2000
佔比0.02%
Global X Russell 2000 ETF
佔比0.02%
iShares Russell 2000 Value ETF
佔比0.02%
Proshares Ultra Russell 2000
佔比0.02%
ProShares Hedge Replication ETF
佔比0.02%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
